SNBL USA is in a unique position to perform ARS studies, from demonstration of efficacy in representative animal models, to pivotal nonclinical studies under the FDA’s Animal Rule.
We are proud of SNBL’s long history of excellence and leadership across our multiple product and service offerings; but more importantly, we benchmark our true success by what we achieve for our customers today and what we do to enable a better future for patients and their families tomorrow.Read More
SNBL USA is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. With its multiple worldwide facilities and countless skilled and experienced scientists and technicians, SNBL Group works together in providing a full range of drug development services.
As a drug class, Nucleic Acid-based Therapeutics represents a diverse spectrum of chemistry, constructs, and delivery options.
Blending our strengths, SNBL USA’s laboratory services division represents a powerful resource to extend discovery and development capabilities while still providing superior, individualized service to each client.
Today, it is our privilege to pay tribute to all of America’s veterans. Your patriotism, love of country, and sense of duty allows us to sleep safe and free at night. We appreciate you for your service and honor you for all of your sacrifices. Thank you.Read More
The American Association for Laboratory Animal Science (AALAS) is currently holding its annual National Meeting at the Phoenix Convention Center. During these five days of the meeting, members and nonmembers come together to learn and benefit from the workshops, lectures, poster sessions, and exhibits. The AALAS National Meeting is the largest gathering in the world of professionals concerned with the production, care, and use of laboratory animals.Read More
Everett, WA – October 27, 2015 – SNBL USA, Ltd., is pleased to announce that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (DHHS). This Indefinite Delivery Indefinite Quantity (IDIQ) contract (HHSO100201500006I), with anticipated issuance of fixed-price and cost reimbursement type task orders, was issued to support the development of chemical, radiological, and nuclear (CRN) countermeasures,...Read More